Home › Trials › NCT06864026

Investigating tirzepatide's effectiveness with ixekizumab for psoriatic arthritis patients with obesity

A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.

PHASE4 · Eli Lilly and Company · NCT06864026

This study tests if adding tirzepatide to ixekizumab can help people with psoriatic arthritis who are overweight or obese feel better over a year.

Quick facts

PhasePHASE4
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company (industry)
Drugs / interventionsixekizumab
Locations55 sites (Avondale, Arizona and 54 other locations)
Trial IDNCT06864026 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness of adding tirzepatide to ixekizumab therapy in patients with active psoriatic arthritis who are also overweight or obese. Participants must have been treated with ixekizumab for approximately three months before starting tirzepatide. The study will last up to 12 months and focuses on individuals with at least one weight-related comorbidity. The goal is to assess how this combination therapy can improve patient outcomes in a real-world clinical setting.

Who should consider this trial

Good fit: Ideal candidates are individuals diagnosed with active psoriatic arthritis and a BMI indicating overweight or obesity, who have been on ixekizumab for about three months.

Not a fit: Patients who have been on ixekizumab for more than four months or have previously used tirzepatide or other GLP-1 receptor agonists may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could enhance treatment options for patients with psoriatic arthritis and obesity, potentially leading to better management of their conditions.

How similar studies have performed: While this specific combination has not been extensively tested, similar approaches involving GLP-1 receptor agonists have shown promise in managing obesity-related conditions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA.
* Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m2 to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
* Who have been treated with ixekizumab for approximately 3 months (±1 month) prior to decision to add tirzepatide.
* Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).

Exclusion Criteria:

* Have currently received ixekizumab for more than 4 months or less than 2 months.
* Had any exposure to tirzepatide or other glucagon-like peptide-1 (GLP-1) receptor agonist (for example, dulaglutide, liraglutide, or semaglutide).
* Are currently enrolled in any other clinical study.
* Have a known hypersensitivity to any component of tirzepatide.
* Have a personal or family history of medullary thyroid cancer.
* Have multiple endocrine neoplasia type 2.
* Have type 1 diabetes mellitus.
* Have a history of chronic or acute pancreatitis at any time before screening.
* Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.
* Have a history of ketoacidosis or hyperosmolar state/coma.
* Have a history of severe hypoglycemia unawareness within the 6 months before screening.
* Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/vomiting.

Where this trial is running

Avondale, Arizona and 54 other locations

+5 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Psoriatic Arthritis, Overweight or Obesity

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.